A phase II multicentre trial of CVP, rituximab and gemcitabine for the treatment of patients with newly diagnosed diffuse large b-cell lymphoma considered unsuitable for r-chop chemotherapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003888-23

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The aim of the trial is evaluate the objective overall response rate of R-GCVP in patients with diffuse large B-cell non-Hodgkin’s lymphoma who cannot receive R-CHOP chemotherapy due to poor cardiac function, and to see whether it is sufficient for further investigation.


Critère d'inclusion

  • Large B cell non-Hodgkin’s lymphoma (DLBCL)

Liens